Last reviewed · How we verify
Oral norfloxacin
Norfloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.
Norfloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Urinary tract infections (uncomplicated and complicated), Bacterial prostatitis, Gastrointestinal infections.
At a glance
| Generic name | Oral norfloxacin |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase, topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Norfloxacin works by binding to and inhibiting DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This leads to accumulation of DNA breaks, cell death, and bactericidal activity. The oral formulation allows systemic absorption for treatment of various bacterial infections.
Approved indications
- Urinary tract infections (uncomplicated and complicated)
- Bacterial prostatitis
- Gastrointestinal infections
- Respiratory tract infections
Common side effects
- Nausea
- Diarrhea
- Headache
- Dizziness
- Abdominal pain
- Photosensitivity
- Tendinitis/tendon rupture
Key clinical trials
- A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events
- An Comparative Pharmacokinetic Study of Amlodipine Besylate Controlled-release Tablets,China in Normal, Healthy, Adult, Human Subjects Under Fasting Conditions (PHASE1)
- Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients (PHASE2)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Midodrine and Albumin in Patients With Refractory Ascites (PHASE3)
- Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis (NA)
- Noroxin Efficacy and Safety Trial (PHASE4)
- Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral norfloxacin CI brief — competitive landscape report
- Oral norfloxacin updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI